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Int J Geriatr Psychiatry. 2019;34:709–721.Objectives: To determine whether individual goal‐oriented cognitive rehabilitation
(CR) improves everyday functioning for people with mild‐to‐moderate dementia.
Design and methods: Parallel group multicentre single‐blind randomised controlled
trial (RCT) comparing CR added to usual treatment (CR) with usual treatment alone
(TAU) for people with an ICD‐10 diagnosis of Alzheimer, vascular or mixed dementia,
and mild‐to‐moderate cognitive impairment (Mini‐Mental State Examination [MMSE]
score ≥ 18), and with a family member willing to contribute. Participants allocated to
CR received 10 weekly sessions over 3 months and four maintenance sessions over
6 months. Participants were followed up 3 and 9 months post randomisation by
blinded researchers. The primary outcome was self‐reported goal attainment at
3 months. Secondary outcomes at 3 and 9 months included informant‐reported goal
attainment, quality of life, mood, self‐efficacy, and cognition and study partner stress
and quality of life.
Results: We randomised (1:1) 475 people with dementia; 445 (CR = 281) were
included in the intention to treat analysis at 3 months and 426 (CR = 208) at 9 months.
At 3 months, there were statistically significant large positive effects for participant‐
rated goal attainment (d = 0.97; 95% CI, 0.75‐1.19), corroborated by informant ratings
(d = 1.11; 95% CI, 0.89‐1.34). These effects were maintained at 9 months for both
participant (d = 0.94; 95% CI, 0.71‐1.17) and informant (d = 0.96; 95% CI, 0.73‐1.2)
ratings. The observed gains related to goals directly targeted in the therapy. There
were no significant differences in secondary outcomes.
Conclusions: CR enables people with early‐stage dementia to improve their
everyday functioning in relation to individual goals targeted in the therapy.- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
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• Cognitive rehabilitation (CR) is an individualized problem‐
solving therapy that aims to manage or reduce functional
disability by addressing personal goals selected by people
with dementia in an everyday context.
• GREAT is the first large trial to show that CR improves
participant and carer evaluations of everyday
functioning in relation to specific, personally
meaningful goals targeted in therapy.
• CR could be considered for inclusion in care pathways for
people with mild‐to‐moderate dementia who require
support to manage everyday life and to maintain
engagement in activities and social participation.1 | INTRODUCTION
Timely diagnosis provides an opportunity to equip people with
dementia, and their family members, to manage the effects of the con-
dition on everyday functioning and independence. Currently, however,
access to nonpharmacological interventions is limited,1 and there is a
particular need for practical, evidence‐based interventions that
directly support the ability to function in everyday life.
People with dementia who have mild‐to‐moderate cognitive impair-
ment typically have relatively preserved ability for procedural learning,
and given appropriate support, there is potential to change behaviour,
implement new strategies, and learn or relearn some important informa-
tion2 in order to improve everyday functioning ormaintain independence.
Cognitive rehabilitation (CR), an intervention that addresses the impact of
cognitive impairment on functional ability,3 has been adapted for people
with dementia.4,5 CR is a person‐centred, goal‐oriented, problem‐solving
therapy aimed at managing or reducing functional disability, mitigating
excess disability,6 and maximising engagement and social participation.
In CR, people with dementia, and where possible their family mem-
bers or other supporters, work collaboratively with a therapist to choose
personally relevant and meaningful goals relating to everyday activities.4,5
The therapist identifies the person's intrinsic capacity and current level of
functioning, assesses the requirements of the task or activity outlined in
the goal, pinpoints areas where the two are mismatched and where prob-
lems arise, and helps devise a plan to overcome these problems using
evidence‐based rehabilitative methods. These methods may include the
use of environmental adaptations and prompts, introduction of compensa-
tory strategies andmemory aids, procedural learning of skills, andmethods
for learning or relearning relevant information. The personal rehabilitation
plan is put into practice over several sessions, which are conducted in the
home setting to ensure that changes are directly implemented in everyday
situations. Progress towards attaining the identified goals is evaluated
through participant‐ and informant‐reported levels of goal attainment.3
Early studies consistent with this approach demonstrated benefits
for people with dementia.7,8 These were confirmed in a series of fea-
sibility studies9,10 and reports from other groups,11,12 followed by a
pilot randomised controlled trial (RCT) that demonstrated superiority
over an active control condition.13 The GREAT trial was designed to
provide definitive evidence about clinical effectiveness.2 | MATERIALS AND METHODS
2.1 | Design
This was a multicentre, single‐blind pragmatic RCT comparing CR
added to usual treatment (CR) with usual treatment alone (TAU).Outcomes were assessed 3 and 9 months post randomisation. The
trial was conducted in eight centres in England and Wales. Ethical
approval was given by the Wales REC 5 National Health Service
(NHS) research ethics committee (Reference 12/WA/0185). Partici-
pants and study partners provided written informed consent. The trial
protocol was published,14 and the trial was registered with Current
Controlled Trials, reference ISRCTN21027481.
2.2 | Participants
Participants were people of any age with an ICD‐10 diagnosis of
Alzheimer, vascular or mixed dementia, and mild‐to‐moderate cogni-
tive impairment as indicated by a Mini‐Mental State Examination
(MMSE)15 score of 18 or above. If taking dementia‐specific medica-
tion, they had to have been receiving a stable dose for at least
1 month, with no expectation of change during the trial. They had to
be able to give informed consent for participation and to have a family
member or other supporter (“study partner”) willing to contribute.
Exclusion criteria were a prior history of stroke, brain injury, or other
significant neurological disorder and, for practical reasons, inability to
communicate in English. Any cases of uncertain eligibility were adjudi-
cated by a panel of four clinicians.
2.3 | Sample size
Power calculations were based on the pilot trial.13 To achieve 80%
power to detect a medium effect size of 0.3, with alpha 0.05, in pri-
mary and secondary outcomes, for a two‐sample comparison of means,
we needed 175 people with dementia, together with their study part-
ners, to complete the trial in each arm. Allowing for estimated potential
attrition of 27%, we needed to randomise 480 people with dementia.
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Participants were recruited through NHS services, support groups, and
Join Dementia Research. Recruitment was conducted by Clinical
Research Network staff from April 1, 2013, to March 31, 2016.2.5 | Randomisation and masking
Participants were individually randomised following consent and base-
line assessment through secure web access to the remote
randomisation centre. Randomisation was conducted by dynamic allo-
cation16 to protect against subversion while maintaining good balance
to the 1:1 allocation ratio. Participants were stratified by centre, gen-
der, age (under 75 vs 75 and above), and MMSE score (under 24 vs 24
and above). To maintain blinding of the trial researchers who con-
ducted follow‐up assessments, outcomes of randomisation were noti-
fied to the trial therapists only, and the trial therapists scheduled all
follow‐up visits by the researchers, irrespective of participants' alloca-
tion. To assess the effectiveness of blinding, at follow‐up, the trial
researchers indicated to which group they believed the participant
was allocated.2.6 | Intervention
The intervention consisted of 10 weekly 1‐hour individual sessions of
goal‐oriented CR over a 3‐month period followed by four 1‐hour
maintenance sessions over the subsequent 6 months, conducted in
the participant's home. CR involved working collaboratively on up to
three rehabilitation goals chosen by the participant, using a problem‐
solving approach. This was supplemented as needed by addressing
motivational and emotional difficulties through applying emotion reg-
ulation and behavioural activation strategies, reviewing and optimising
participants' existing use of strategies to manage cognitive disability,
providing practice in maintaining attention and concentration,
signposting to relevant services, and offering support for study part-
ners. CR could potentially be delivered by therapists from various pro-
fessional backgrounds; in this trial, the therapists were nine
occupational therapists and one nurse. Therapists attended a 2‐day
initial training course and annual 1‐day refresher training sessions
and received regular centralised supervision to ensure fidelity to pro-
tocol and consistency across sites. Therapists completed therapy logs,
which were reviewed by the supervisor.2.7 | Comparator
The comparator was treatment as usual, typically consisting of
medication, monitoring, and general psychosocial support.2.8 | Outcomes
All assessments were conducted in participants' homes by trained
researchers blind to group allocation.The primary outcome was participant‐rated goal attainment at
3 months, recorded using a previously validated client‐centred attain-
ment measure, a simple 0 to 10 scale that is accessible and feasible for
people with cognitive impairment to complete; an improvement of 2
points in the goal attainment rating for any individual goal is consid-
ered to be clinically significant.17-22 Participants' individual goals were
collaboratively identified through a semistructured interview, the Ban-
gor Goal‐Setting Interview (BGSI).23 All participants chose up to three
goals at baseline and rated current attainment; attainment ratings
were then averaged across each participant's goals to give a single
summary rating. These ratings were repeated at the 3‐month follow‐
up, providing the primary outcome. Participants also rated goal attain-
ment at 9 months, study partners independently rated participant goal
attainment at 3 and 9 months, and participants rated their satisfaction
with their goal attainment at 3 and 9 months.
Other secondary outcomes for participants with dementia at 3
and 9 months were self‐reported self‐efficacy (Generalised Self‐
Efficacy Scale),24 mood (Hospital Anxiety and Depression Scale),25
and dementia‐specific health‐related quality of life (DEMQOL).26 Par-
ticipants also completed a brief cognitive test battery covering mem-
ory (story recall from the Rivermead Behavioural Memory Test),27
attention (elevator counting and elevator counting with distraction
subtests from the Test of Everyday Attention),28 and executive func-
tion (verbal letter fluency from the Delis‐Kaplan Executive Function
System).29
Secondary outcomes for study partners at 3 and 9 months
were self‐reported stress (Relatives' Stress Scale),30 quality of life
(WHOQOL‐BREF),31 and health‐related quality of life (EQ 5D).322.9 | Analysis
Analyses were conducted in IBM SPSS v.22 and R v.3.3.1. The main
statistical analysis, conducted blind, was an intention to treat analysis.
Missing data were addressed through multiple imputation of missing
values using a predictive mean matching algorithm.33 Missing outcome
measure scores at baseline were imputed using centre‐level factors
and the participant's gender, age, and baseline MMSE score. Missing
outcome measure scores at the 3‐ and 9‐month assessments were
estimated based on centre‐level factors, baseline characteristics, and
scores for the same outcome at the earlier time‐point(s). In line with
simulation‐based observations of the D2 statistic's performance for
pooling P values,34 25 sets of imputations were generated using the
method described above. For both primary and secondary outcomes,
the analysis was a mixed‐effects analysis of covariance (ANCOVA)
adjusted for baseline score, allocation group, and the stratification var-
iables (age group, gender, MMSE score, and centre). Baseline score,
allocation group, age group, gender, and MMSE score were treated
as fixed effects and centre as a random effect. Between‐group effect
sizes with confidence intervals (CIs) were calculated using Cohen d
(the mean difference between the two arms, divided by the pooled
standard deviation). For the primary outcome measure, prespecified
regression modelling was undertaken to identify potential effect‐
712 CLARE ET AL.modifying factors, selected on clinical and theoretical grounds.
Prespecified exploratory analyses, not adjusted for multiple compari-
sons, examined the impact of the number of sessions received on pri-
mary and secondary outcomes at 3‐ and 9‐month follow‐up and
investigated whether participants' baseline ratings of goal importance
and readiness to change were associated with outcomes.
Sensitivity analyses compared the outcomes of analyses that
included both imputed and complete case datawith the outcomes of anal-
yses that included complete cases only. An analysis based on treatment
received irrespective of group allocation was planned, but proved unnec-
essary as group allocation and treatment received were 100% consistent.
Interviews were conducted with a consecutive series of partici-
pants and study partners completing the intervention in three of the
trial sites by an interviewer independent of the trial. Interviews
followed a semistructured schedule in which participants and study
partners were asked about their experiences and perceptions of the
intervention, its usefulness, the degree of effort required, and any
impact on day‐to‐day life. Data were analysed thematically from a crit-
ical realist perspective, taking an inductive approach in identifying and
exploring patterns of meaning. Initial coding of the first five transcripts
was undertaken by two researchers working independently. The
resulting lists of themes were compared and discussed until consensus
was reached about content and organisation, after which each
researcher recoded the transcripts. Related themes were clustered
together, and the clusters ordered into group‐level themes and sub-
themes, and integrated into an overall thematic map by both
researchers working together. The remaining transcripts were then
coded by a single researcher. Findings are presented only briefly here
but will be reported more fully in a separate paper.2.10 | Patient and public involvement
Alzheimer's Society Research Network volunteers contributed to
development of the trial protocol and served as experts by experience
on the Trial Steering Committee (TSC).2.11 | Changes to protocol
The trial was initially set up with six sites, but two further sites were
added to ensure recruitment targets were met. Interviews with a sub-
set of participants and study partners were added on the recommen-
dation of the experts by experience.3 | RESULTS
The flow of participants through the trial is shown in Figure 1.
Following baseline assessment, 475 participants were randomised to
either CR (n = 239) or TAU (n = 236). One participant who did not
meet diagnostic criteria was incorrectly randomised and was
withdrawn from analysis. All participants received their allocatedcondition, and 90% of CR participants completed at least 10 sessions.
Six participants in the CR group withdrew from the intervention after
at least two sessions but remained in the trial to complete follow‐up
assessments. Retention in the trial was 94% at 3 months and 90% at
9 months. Of 36 couples invited to participate in an interview follow-
ing the 9‐month follow‐up, 26 agreed, although in one case only the
study partner completed the interview.3.1 | Sample characteristics
Demographic and clinical characteristics of the participants with
dementia and study partners are summarised in Table 1. There were
111 serious adverse events reported during the trial, affecting 68 par-
ticipants and 26 study partners and mostly involving hospitalisation;
blinded assessors judged that none were related to trial participation.3.2 | Numbers analysed
The intention to treat analysis included data from 474 participants at
baseline (CR n = 238; TAU n = 236), 445 participants at 3 months
(CR n = 218; TAU n = 227), and 426 participants at 9 months (CR
n = 208; TAU n = 218).3.3 | Main outcome analyses
The primary outcome was participants' goal attainment ratings on the
BGSI at 3 months. Participant attainment and satisfaction ratings and
study partner attainment ratings across all time points, and details of the
statistical analyses, are summarised in Table 2. According to these
participant‐reported outcomes, CRwas effective in improving functioning
in the targeted areas at 3 months from the perspective of both partici-
pants and study partners, and this improvement was maintained at
9 months. Note that the analyses reported inTable 2 cover all goals that
were identified at baseline, and for the CR group, this included a number
of goals that were not addressed in the intervention. The CR group
participants identified 679 goals and worked on 481 (71%) of these with
the therapists. Taking just the 481 goals that were addressed in therapy,
the mean change in participants' goal attainment ratings was an
improvement of 2.84 points (SD 2.84) at 3 months and 2.77 points (SD
3.18) at 9 months, while study partners' ratings showed an improvement
of 3.09 points (SD 2.73) at 3 months and 2.76 points (SD 3.14) at
9 months.
For the primary outcome measure at 3 months, linear mixed‐
effects models examining participant (centre, MMSE score, diagnosis,
medication use, education, socio‐economic status, and blinding effec-
tiveness) and study partner (centre, gender, age, education, hours
spent helping the participant, and type of relationship with the partic-
ipant) factors predicting change in participants' goal attainment ratings
from baseline to follow‐up in the CR group were not statistically sig-
nificant apart from socio‐economic status, where higher socio‐
economic status was associated with better outcomes; see Supporting
Information Table S1. Participants' baseline ratings of the importance
FIGURE 1 Participant flow through the GREAT trial
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change in relation to the goal were significantly associated with
improvement in attainment ratings (t403 = 2.66, r = 0.13, P = 0.008),
as was adherence, defined as number of CR sessions completed
(b = 0.17; SE = 0.09; t215 = 2.01; P = 0.046; 95% CI, 0‐0.34).
Scores on secondary outcome measures at all time‐points, and
ANCOVA analyses, are presented inTable 3. Following Bonferroni cor-
rection, there were no significant differences. Effect sizes were small to
negligible, although in some cases with wide confidence intervals.3.4 | Sensitivity analyses
Results from the analysis of complete case data were very similar to
those of the multiple imputation analysis and did not alter the pattern
of findings; see Tables S2 and S3. The difference in attrition betweenCR and TAU was minimal, and no statistically significant differences
were observed in baseline characteristics or in primary and secondary
outcomes for participants who withdrew and remained in the study;
see Tables S4 and S5. Consequently, multiple imputation did not need
to be modified.3.5 | Qualitative evaluation
Participants and study partners who were interviewed after complet-
ing the trial responded positively to the intervention, although for
some study partners this was tempered by the knowledge that
dementia would continue to progress. Participants and study part-
ners valued the relationship with the therapist, both for the specific
focus on developing and personalising strategies and for the more
general information and support provided. Interviewees said that
TABLE 1 Demographic and clinical characteristics of the participants and study partners
Measure
Whole Sample
n = 474
CR
n = 238
TAU
n = 236
(a) Participants with dementiaa
Age, mean (SD), range 78.56 (7.07); 53 to 95 78.25 (7.13); 53 to 95 78.87 (7.01); 55 to 95
Sex (male), n (%) 248 (52.3) 124 (52.1) 124 (52.5)
Ethnicity, n (%):
White 457 (96.4) 226 (95.0) 231 (97.9)
Mixed/multiple ethnic group 2 (0.4) 2 (0.8) 0 (0)
Asian/Asian British 6 (1.2) 3 (1.3) 3 (1.3)
Black/African/Caribbean/black British 7 (1.5) 5 (2.1) 2 (0.9)
Other ethnic group 2 (0.4) 2 (0.8) 0 (0)
First language (English), n (%) 445 (93.9) 222 (93.3) 223 (94.5)
Marital status (married), n (%) 330 (69.6) n = 474 167 (70.2) n = 238 163 (69.1) n = 236
Years of education 12.57 (3.37); 5 to 33 n = 471 12.57 (3.33); 6 to 24 n = 236 12.58 (3.42); 5 to 33 n = 235
Occupational status, n (%):
I Professional 52 (11.0) 23 (9.7) 29 (12.3)
II Managerial/technical 157 (33.1) 81 (34.0) 76 (32.2)
III N Skilled, nonmanual 103 (21.7) 54 (22.7) 49 (20.8)
III M Skilled, manual 80 (16.9) 41 (17.2) 39 (16.5)
IV Partly skilled 50 (10.5) 24 (10.1) 26 (11.0)
V Unskilled 32 (6.8) 15 (6.3) 17 (7.2)
Diagnosis, n (%):
Alzheimer's disease 284 (59.9) 139 (58.4) 145 (61.4)
Vascular dementia 74 (15.6) 43 (18.1) 31 (13.1)
Mixed 116 (24.5) 56 (23.5) 60 (25.4)
MMSE score, mean (SD), range 23.82 (3.02); 18 to 30 23.89 (3.04); 18 to 30 23.75 (3.02); 18 to 30
Charlson comorbidity index weighted score,
mean (SD), range
2.52 (1.47); 1 to 11 2.49 (1.47); 1 to 11 2.55 (1.48); 1 to 10
Subjective rating of health, n (%):
Excellent 39 (8.2) 20 (8.4) 19 (8.1)
Very good 125 (26.4) 65 (27.3) 60 (25.4)
Good 159 (33.5) 77 (32.4) 82 (34.7)
Fair 121 (25.5) 61 (25.6) 60 (25.4)
Poor 30 (6.3) 15 (6.3) 15 (6.4)
DEMQOL, mean (SD), range 92.30 (12.33); 39 to 112; n = 472 92.00 (12.90); 39 to 112; n = 237 92.61 (11.75); 39 to 112; n = 235
GSES, mean (SD), range 30.94 (5.09); 11 to 40; n = 469 30.75 (4.81); 13 to 40; n = 237 31.13 (5.35); 11 to 40; n = 232
HADS, mean (SD), range: n = 472 n = 238 n = 234
Depression 3.77 (2.79); 0 to 14 3.87 (2.83); 0 to 12 3.67 (2.75); 0 to 14
Anxiety 5.14 (3.64); 0 to 16 5.29 (3.67); 0 to 16 4.98 (3.62); 0 to 16
RBMT, mean (SD), range: n = 473 n = 237 n = 236
Immediate recall 2.66 (2.11); 0 to 11.5 2.58 (2.10); 0 to 9.5 2.73 (2.12); 0 to 11.5
Delayed recall 0.38 (1.96); −1 to 9 0.39 (1.94); −1 to 8 0.37 (1.97); −1 to 9
TEA, mean (SD), range:
Elevator counting 6.39 (1.16); 0 to 7 n = 463 6.35 (1.27); 0 to 7 n = 232 6.42 (1.05); 1 to 7 n = 231
Elevator counting with distraction 4.55 (2.72); 0 to 9; n = 448 4.39 (2.68); 0 to 9; n = 223 4.72 (2.75); 0 to 9; n = 225
DKEFS verbal fluency, mean (SD), range 26.27 (11.82); 2 to 64; n = 470 25.78 (11.61); 2 to 64; n = 235 26.77 (12.03); 3 to 58; n = 235
Medication use, n (%) reporting use of: n = 438 n = 215 n = 223
Dementia medications 332 (75.8) 157 (73.0) 175 (78.5)
Hypnotics and anxiolytics 3 (0.7) 1 (0.5) 2 (0.9)
Anti‐psychotic medication 6 (1.4) 2 (0.9) 4 (1.8)
Antidepressants 98 (22.4) 57 (26.5) 41 (18.4)
Anti‐epileptics 2 (0.5) 1 (0.5) 1 (0.5)
(Continues)
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TABLE 1 (Continued)
Measure
Whole Sample
n = 474
CR
n = 238
TAU
n = 236
(b) Study partnersb
Relationship to participant with dementia, n (%):
Spouse/partner 331 (69.8) 167 (70.2) 164 (69.5)
Adult child (including in‐law) 118 (24.9) 58 (24.3) 60 (25.4)
Other 25 (5.3) 13 (5.5) 12 (5.1)
Age, mean (SD), range 68.74 (13.01); 17 to 92 68.45 (13.76); 17 to 92 69.04 (12.24); 23 to 92
Sex (male), n (%) 142 (30.0) 75 (31.5) 67 (28.4)
Ethnicity, n (%):
White 449 (94.7) 224 (94.1) 225 (95.3)
Mixed/multiple ethnic group 5 (1.1) 4 (1.7) 1 (0.4)
Asian/Asian British 10 (2.1) 4 (1.7) 6 (2.5)
Black/African/Caribbean/black British 8 (1.7) 6 (2.5) 2 (0.8)
Other ethnic group 2 (0.42) 0 (0) 2 (0.9)
First language (English), n (%) 443 (93.5) 222 (93.3) 221 (93.6)
Marital status (married), n (%) 393 (82.9) 187 (78.6) 206 (87.3)
Years of education, mean (SD), range 13.49 (3.52); 4 to 26; n = 472 13.67 (3.45); 5 to 25; n = 237 13.32 (3.58); 4 to 26; n = 235
Occupational status, n (%):
I Professional 49 (10.3) 30 (12.6) 19 (8.1)
II Managerial/technical 158 (33.3) 74 (31.1) 84 (35.6)
III N Skilled, nonmanual 137 (28.9) 64 (26.9) 73 (30.9)
III M Skilled, manual 47 (9.9) 24 (10.1) 23 (9.7)
IV Partly skilled 55 (11.6) 27 (11.3) 28 (11.9)
V Unskilled 20 (4.2) 14 (5.9) 6 (2.5)
NA 8 (1.7) 5 (2.1) 3 (1.3)
Stress (RSS), mean (SD), range n = 471; 18.96 (9.44); 0 to 52 n = 236; 18.85 (9.04); 2 to 46 n = 235; 19.08 (9.83);0 to 52
WHOQOL domains, mean (SD), range:
Physical n = 470; 15.34 (2.95); 5 to 20 n = 237; 15.30 (3.00); 5 to 20 n = 233; 15.37 (2.90); 7 to 20
Psychological n = 470; 15.14 (2.15); 8 to 20 n = 237; 15.13 (2.19); 8 to 20 n = 233; 15.15 (2.10); 8 to 20
Social n = 468; 15.13 (2.66); 5 to 20 n = 235; 15.19 (2.67); 5 to 20 n = 233; 15.07 (2.66); 7 to 20
Environmental n = 470; 16.43 (2.15); 10 to 20 n = 237; 16.35 (2.30); 10 to 20 n = 233; 16.52 (1.99); 10 to 20
EQ 5D3L, mean (SD), range:
Index n = 468; 0.78 (0.25); −0.18 to 1 n = 235; 0.77 (0.25); −0.18 to 1 n = 233; 0.79 (0.24); −0.07 to 1
VAS n = 467; 74.48 (19.95); 0 to 100 n = 234; 73.52 (20.95); 1 to 100 n = 233; 75.44 (18.90); 0 to 100
aData are mean (SD) range, or n (%). CR, cognitive rehabilitation; TAU, treatment as usual; MMSE, Mini–Mental State Examination (higher scores indicate
better performance); DEMQOL, people with dementia quality of life questionnaire (higher scores indicate better quality of life); GSES, Generalized
Self‐Efficacy Scale (higher scores indicate stronger sense of perceived self‐efficacy); HADS, Hospital Anxiety and Depression Scale (higher scores indicate
higher levels of anxiety and depression); RBMT, Rivermead Behavioural Memory Test (higher scores indicate better performance); TEA, Test of Everyday
Attention (higher scores indicate better performance); D‐KEFS, Delis‐Kaplan Executive Function System (higher scores indicate better performance).
bData are mean (SD) range, or n (%). CR, cognitive rehabilitation; TAU, treatment as usual; RSS, Relatives' Stress Scale (higher scores indicate higher levels of
caregiving‐specific stress); WHOQOL‐BREF, World Health Organisation Quality of Life Instrument—brief version (higher scores indicate better quality of
life); EQ 5D3L, European Quality of Life 5 Dimensions questionnaire Level version (higher score indicates higher health status); VAS, Visual Analogue Scale
(higher score indicates higher health status).
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day activities and had improved their adjustment to living with
dementia, resulting in less anxiety, better coping skills, feelings of
empowerment, and improved well‐being and quality of life. Some
commented that the intervention increased their problem‐solving
ability and enabled them to develop new strategies for different
situations.4 | DISCUSSION
The GREAT trial demonstrates that individualised, goal‐oriented CR is an
effective intervention for people with early‐stage Alzheimer disease and
vascular or mixed dementia wishing to improve aspects of their everyday
functioning. Outcomes elicited from participants and study partners indi-
cated that CR improved functioning in the areas targeted in the therapy
TABLE 2 Goal attainment ratings at baseline, 3‐month and 9‐month follow‐up, and statistical comparisons
(a) Goal attainment ratingsa
Measure CR TAU
Baseline
(n = 238)
3 mo
(n = 218)
9 mo
(n = 205)
Baseline
(n = 236)
3 mo
(n = 227)
9 mo
(n = 211)
Participant rating of attainment 3.53 (1.74) 6.10 (1.99) 6.05 (2.21) 3.55 (1.59) 4.41 (1.84) 4.22 (2.00)
Participant rating of satisfaction 3.76 (1.76) 6.47 (1.88) 6.75 (1.97) 3.86 (1.49) 5.05 (1.94) 5.26 (2.05)
Study partner rating of attainment 2.76 (1.43) 5.46 (1.94) 5.21 (2.33) 2.72 (1.32) 3.55 (1.73) 3.31 (1.96)
(b) Statistical comparison at 3‐month follow‐upb
Measure P Bonferroni
Adjusted Pc
Mean
Difference
95% CI for
Mean Difference
d 95% CI for d
Participant rating of attainment <0.001 NA 1.58 1.27 to 1.90 0.81 0.62 to 1
Participant rating of satisfaction <0.001 <0.001 1.34 1.01 to 1.66 0.7 0.51 to 0.88
Study partner rating of attainment <0.001 <0.001 1.75 1.42 to 2.07 0.93 0.74 to 1.12
(c) Statistical comparison at 9‐month follow‐upd
Measure P Bonferroni
Adjusted Pe
Mean Difference 95% CI for
Mean Difference
d 95% CI for d
Participant rating of attainment <0.001 <0.001 1.71 1.35 to 2.08 0.8 0.61 to 0.99
Participant rating of satisfaction <0.001 <0.001 1.36 1 to 1.73 0.67 0.49 to 0.86
Study partner rating of attainment <0.001 <0.001 1.70 1.32 to 2.09 0.79 0.60 to 0.97
aData are mean (SD). CR, cognitive rehabilitation; TAU, Treatment as usual.
bAnalysis of covariance (ANCOVA) adjusted for baseline score, allocation group and stratification variables, age, gender, MMSE score and site. CI, confi-
dence intervals. NA, not applicable, as no correction was planned for the primary outcome. The d effect size estimates were based on a fixed effect size
model as they cannot be derived directly from the mixed‐effects model and were calculated by converting eta squared to r, and then converting r to d.
cNineteen adjustments in total to adjust for all the participant and carer outcome measure comparisons, except for the primary outcome.
dANCOVA adjusted for baseline score, allocation group and stratification variables, age, gender, MMSE score and site. CI, confidence intervals. The d effect
size estimates were based on a fixed effect size model as they cannot be derived directly from the mixed‐effects model and were calculated by converting
eta squared to r, and then converting r to d.
eTwenty adjustments in total to adjust for all the participant and carer outcome measure comparisons.
716 CLARE ET AL.at 3 months, and this improvement was maintained at 9 months. When
considering the goals actually addressed in therapy, improvements met
criteria for clinical significance. High levels of adherence and low attrition
indicated that the intervention was acceptable to participants and study
partners. Participants and study partners interviewed in depth viewed
the intervention positively and felt that it was beneficial.
4.1 | Strengths and limitations
A key strength is that the intervention targeted real‐life situations and
aimed to improve participants' functioning in areas that were meaningful
to them, avoiding any problems relating to lack of transfer or generalisa-
tion of effects. The primary outcome was a proximal measure, directly
evaluating perceptions of change in the areas targeted in the
intervention. No trial‐related adverse events or harms were identified.
There are several limitations to consider. Due to the constraints of
trial design, the goal‐setting interview was conducted by researchers
not involved in delivering therapy, whereas in clinical practice, the
goal‐setting process would be undertaken by the therapist and might
be more efficient. While participants were invited to select up to three
goals, on average, the therapists were able to address two goals per
participant. The primary outcome was based on ratings of progress
with all goals identified at baseline, rather than just those goals thatwere actually addressed; therefore, the overall estimate of improve-
ment in goal attainment is a conservative one. Ratings for the goals
that were directly addressed showed a clinically meaningful degree
of change. The trial design did not allow us to conclusively demon-
strate that benefits were due to the specific effects of CR rather than
nonspecific effects of contact with a therapist; however, the observed
gains related specifically to improvements in functional ability for
goals directly targeted in the therapy, and in the pilot trial, CR demon-
strated benefits over an active control condition. In selecting second-
ary outcome measures, it would have been useful to include a
measure of functional ability.4.2 | How the findings relate to other evidence
The results confirm the finding from our pilot trial13 that CR is effec-
tive in improving those aspects of everyday functioning targeted in
the intervention. A different, but related, approach to improving
everyday functioning involves structured training in completing
selected activities of daily living. Two recent trials35,36 found that per-
formance on trained tasks improved, although there was no evidence
of generalisation to everyday situations35 or improvement in second-
ary outcomes such as quality of life. The only other large‐scale trial
TABLE 3 Scores on secondary outcome measures at baseline, 3‐month and 9‐month follow‐up, and statistical comparisons
(a) Scores for participants with dementiaa
Measure CR TAU
Baseline 3 mo 9 mo Baseline 3 mo 9 mo
DEMQOL n = 237 n = 218 n = 204 n = 235 n = 227 n = 213
92.00 92.79 92.36 92.61 93.20 92.25
(12.90) (11.95) (12.00) (11.75) (12.00) (12.82)
39 to 112 51 to 112 54 to 112 47 to 111 51 to 111 45 to 112
GSES n = 237 n = 215 n = 194 n = 232 n = 224 n = 207
30.75 30.98 30.76 31.13 30.59 30.62
(4.81) (4.62) (4.91) (5.35) (5.61) (5.60)
13 to 40 18 to 40 15 to 40 11 to 40 11 to 40 10 to 40
HADS depression n = 238 n = 218 n = 194 n = 234 n = 226 n = 210
3.87 3.90 4.19 3.67 3.74 3.83
(2.83) (2.86) (3.23) (2.75) (2.69) (2.82)
0 to 12 0 to 15 0 to 17 0 to 14 0 to 12 0 to 17
HADS anxiety n = 238 n = 216 n = 193 n = 234 n = 226 n = 210
5.29 5.13 5.63 4.98 4.61 4.88
(3.67) (3.66) (3.83) (3.62) (3.41) (3.37)
0 to 16 0 to 17 0 to 18 0 to 16 0 to 15 0 to 20
RBMT immediate recall n = 237 n = 218 n = 200 n = 236 n = 226 n = 211
2.58 2.88 2.34 2.73 2.79 2.37
(2.10) (2.16) (2.09) (2.12) (2.12) (1.96)
0 to 9.50 0 to 10 0 to 10 0 to 11.50 0 to 11 0 to 10
RBMT delayed recall n = 237 n = 217 n = 200 n = 236 n = 225 n = 210
0.39 0.94 0.23 0.37 0.66 0.36
(1.94) (2.31) (1.97) (1.97) (2.16) (1.97)
−1 to 8 −1 to 8.50 −1 to 8.50 −1 to 9 −1 to 11 −s1 to 9.50
TEA elevator counting n = 232 n = 210 n = 191 n = 231 n = 219 n = 206
6.35 6.31 6.21 6.42 6.36 6.24
(1.27) (1.23) (1.41) (1.05) (1.22) (1.32)
0 to 7 0 to 7 0 to 7 1 to 7 0 to 7 1 to 7
TEA elevator counting with distraction n = 223 n = 198 n = 177 n = 225 n = 208 n = 193
4.39 4.62 4.66 4.72 4.90 4.52
(2.68) (3.08) (3.11) (2.75) (3.15) (3.07)
0 to 9 0 to 10 0 to 10 0 to 9 0 to 10 0 to 10
DKEFS verbal fluency n = 235 n = 217 n = 198 n = 235 n = 227 n = 211
25.78 26.29 26.30 26.77 26.80 25.90
(11.61) (12.56) (13.32) (12.03) (12.38) (12.36)
2 to 64 0 to 58 0 to 62 3 to 58 3 to 68 1 to 67
(b) Scores for study partnersb
Measure CR TAU
Baseline 3 mo 9 mo Baseline 3 mo 9 mo
RSS n = 236 n = 212 n = 200 n = 235 n = 221 n = 211
18.85 19.42 21.23 19.08 20.42 21.65
(9.04) (9.62) (9.92) (9.83) (10.33) (10.74)
2 to 46 2 to 46 2 to 51 0 to 52 1 to 54 2 to 50
WHOQOL physical n = 237 n = 212 n = 199 n = 233 n = 220 n = 210
15.30 15.20 14.95 15.37 15.07 14.78
(3.00) (2.93) (3.14) (2.90) (2.86) (2.97)
5 to 20 5 to 20 6 to 20 7 to 20 6 to 20 6 to 20
WHOQOL psychological n = 237 n = 212 n = 199 n = 233 n = 220 n = 210
15.13 14.98 14.74 15.15 14.74 14.53
(2.19) (2.21) (2.41) (2.10) (2.20) (2.38)
8 to 20 7 to 20 7 to 20 8 to 20 7 to 20 7 to 20
WHOQOL social n = 235 n = 211 n = 197 n = 233 n = 219 n = 210
15.19 15.03 15.04 15.07 14.80 14.51
(2.67) (2.47) (2.72) (2.66) (2.58) (2.83)
5 to 20 7 to 20 8 to 20 7 to 20 7 to 20 5 to 20
WHOQOL environmental n = 237 n = 212 n = 199 n = 233 n = 220 n = 210
16.35 16.33 16.00 16.52 16.18 16.04
(2.30) (2.26) (2.40) (1.99) (2.04) (2.05)
10 to 20 9 to 20 9 to 20 10 to 20 10 to 20 11 to 20
EQ 5D3L index n = 235 n = 209 n = 196 n = 233 n = 217 n = 211
(Continues)
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TABLE 3 (Continued)
0.77 0.75 0.73 0.79 0.74 0.75
(0.25) (0.24) (0.27) (0.24) (0.25) (0.23)
−0.18 to 1 −0.18 to 1 −0.18 to 1 −0.07 to 1 −0.24 to 1 −0.07 to 1
EQ 5D3L VAS n = 234 n = 208 n = 198 n = 233 n = 217 n = 211
73.52 74.13 74.14 75.44 73.14 72.42
(20.95) (18.92) (19.16) (18.90) (18.95) (19.13)
1 to 100 0 to 100 10 to 100 0 to 100 0 to 100 0 to 100
(c) Statistical analyses at 3‐month follow‐upc
Measure Pd Bonferroni
Adjusted P
Mean Difference 95% CI for
Mean Difference
d 95% CI for d
Participants with dementia
DEMQOL 0.738 1.000 0.24 −1.27 to 1.75 0.02 −0.16 to 0.20
GSES 0.126 1.000 0.58 −0.16 to 1.32 0.11 −0.07 to 0.29
HADS depression 0.861 1.000 0.00 −0.42 to 0.41 0.02 −0.16 to 0.20
HADS anxiety 0.478 1.000 0.17 −0.30 to 0.65 0.06 −0.12 to 0.24
RBMT immediate recall 0.189 1.000 0.19 −0.10 to 0.48 0.10 −0.08 to 0.28
RBMT delayed recall 0.096 1.000 0.24 −0.04 to 0.52 0.12 −0.06 to 0.30
TEA elevator counting 0.799 1.000 0.01 −0.19 to 0.21 0.02 −0.16 to 0.20
TEA elevator counting with distraction 0.784 1.000 0.01 −0.45 to 0.47 0.03 −0.15 to 0.21
DKEFS verbal fluency 0.794 1.000 0.15 −1.12 to 1.41 0.02 −0.16 to 0.20
Study partners
RSS 0.382 1.000 −0.50 −1.61 to 0.62 0.05 −0.13 to 0.23
WHOQOL physical 0.431 1.000 0.12 −0.18 to 0.42 0.04 −0.14 to 0.22
WHOQOL psychological 0.214 1.000 0.18 −0.10 to 0.47 0.08 −0.10 to 0.26
WHOQOL social 0.572 1.000 0.10 −0.25 to 0.45 0.05 −0.13 to 0.23
WHOQOL environmental 0.050 0.947 0.26 0 to 0.51 0.13 −0.06 to 0.31
EQ 5D3L index 0.295 1.000 0.02 −0.01 to 0.05 0.07 −0.11 to 0.25
EQ 5D visual analogue scale 0.286 1.000 1.58 −1.31 to 4.47 0.09 −0.09 to 0.27
(d) Statistical analyses at 9‐month follow‐upe
Measures Pf Bonferroni
Adjusted P
Mean Difference 95% CI for
Mean Difference
d 95% CI for d
Participants with dementia
DEMQOL 0.215 1.000 1.08 −0.62 to 2.78 0.09 −0.09 to 0.27
GSES 0.38 1.000 0.37 −0.45 to 1.18 0.07 −0.11 to 0.25
HADS depression 0.614 1.000 0.12 −0.35 to 0.6 0.05 −0.13 to 0.23
HADS anxiety 0.334 1.000 0.26 −0.26 to 0.77 0.08 −0.1 to 0.26
RBMT immediate recall 0.496 1.000 0.10 −0.19 to 0.4 0.06 −0.12 to 0.24
RBMT delayed recall 0.466 1.000 −0.10 −0.37 to 0.17 0.06 −0.12 to 0.24
TEA elevator counting 0.718 1.000 −0.01 −0.27 to 0.25 0.04 −0.14 to 0.22
TEA elevator counting with distraction 0.334 1.000 0.23 −0.23 to 0.69 0.09 −0.09 to 0.27
DKEFS verbal fluency 0.342 1.000 0.71 −0.75 to 2.16 0.06 −0.12 to 0.24
Study partners
RSS 0.808 1.000 0.08 −1.09 to 1.25 0.02 −0.16 to 0.2
WHOQOL physical 0.399 1.000 0.14 −0.19 to 0.47 0.05 −0.13 to 0.23
WHOQOL psychological 0.346 1.000 0.15 −0.16 to 0.45 0.06 −0.12 to 0.24
WHOQOL social 0.049 0.93 0.41 0 to 0.81 0.15 −0.03 to 0.33
WHOQOL environmental 0.371 1.000 0.13 −0.15 to 0.4 0.06 −0.12 to 0.24
EQ 5D3L index 0.547 1.000 −0.01 −0.04 to 0.02 0.04 −0.14 to 0.22
EQ 5D visual analogue scale 0.071 1.000 2.60 −0.22 to 5.42 0.14 −0.04 to 0.32
aData are mean (SD) range. CR, cognitive rehabilitation; TAU, treatment as usual; DEMQOL People with DEMentia Quality Of Life questionnaire (higher
scores indicate better quality of life); GSES, Generalized Self‐Efficacy Scale (higher scores indicate stronger sense of perceived self‐efficacy); HADS, Hos-
pital Anxiety and Depression Scale (higher scores indicate higher levels of anxiety and depression); RBMT, Rivermead Behavioural Memory Test (higher
scores indicate better performance); TEA, Test of Everyday Attention (higher scores indicate better performance); D‐KEFS, Delis‐Kaplan Executive Function
System (higher scores indicate better performance).
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bData are mean (SD) range. CR, cognitive rehabilitation; TAU, treatment as usual; RSS, Relatives' Stress Scale (higher scores indicate higher levels of care-
giving‐specific stress); WHOQOL‐BREF, World Health Organisation Quality of Life Instrument—brief version (higher scores indicate better quality of life);
EQ 5D3L, European Quality of Life 5 Dimensions questionnaire Level version (higher score indicates higher health status); VAS, Visual Analogue Scale
(higher score indicates higher health status).
cDEMQOL, People with DEMentia Quality Of Life questionnaire (higher scores indicate better quality of life); GSES, Generalized Self‐Efficacy Scale (higher
scores indicate stronger sense of perceived self‐efficacy); HADS, Hospital Anxiety and Depression Scale (higher scores indicate higher levels of anxiety and
depression); RBMT, Rivermead Behavioural Memory Test (higher scores indicate better performance); TEA, Test of Everyday Attention (higher scores indi-
cate better performance); D‐KEFS, Delis‐Kaplan Executive Function System (higher scores indicate better performance). RSS, Relatives' Stress Scale (higher
scores indicate higher levels of caregiving‐specific stress); WHOQOL‐BREF, World Health Organisation Quality of Life Instrument—brief version (higher
scores indicate better quality of life); EQ 5D3L, European Quality of Life 5 Dimensions questionnaire Level version (higher score indicates higher health
status); VAS, Visual Analogue Scale (higher score indicates higher health status). The d effect size estimates were based on a fixed effect size model as they
cannot be derived directly from the mixed‐effects model and were calculated by converting eta squared to r, and then converting r to d.
dNineteen adjustments in total to adjust for all the participant and carer outcome measure comparisons, except for the primary outcome.
eDEMQOL People with DEMentia Quality Of Life questionnaire (higher scores indicate better quality of life); GSES, Generalized Self‐Efficacy Scale (higher
scores indicate stronger sense of perceived self‐efficacy); HADS, Hospital Anxiety and Depression Scale (higher scores indicate higher levels of anxiety and
depression); RBMT, Rivermead Behavioural Memory Test (higher scores indicate better performance); TEA, Test of Everyday Attention (higher scores indi-
cate better performance); D‐KEFS, Delis‐Kaplan Executive Function System (higher scores indicate better performance). RSS, Relatives' Stress Scale
(higher scores indicate higher levels of caregiving‐specific stress); WHOQOL‐BREF, World Health Organisation Quality of Life Instrument—brief version
(higher scores indicate better quality of life); EQ 5D3L, European Quality of Life 5 Dimensions questionnaire Level version (higher score indicates higher
health status); VAS, Visual Analogue Scale (higher score indicates higher health status). The d effect size estimates were based on a fixed effect size model
as they cannot be derived directly from the mixed‐effects model and were calculated by converting eta squared to r, and then converting r to d.
fTwenty adjustments in total to adjust for all the participant and carer outcome measure comparisons.
CLARE ET AL. 719of CR37 reported that, compared with usual treatment, CR participants
showed less functional decline at 24 months, a 6‐month delay in
institutionalisation and lower overall rates of institutionalisation, but no
significant differences mood or quality of life. The CR intervention in that
trial was poorly described, and goal attainmentwas not directlymeasured.
These findings taken together indicate that it is possible to pro-
mote improved functional ability through both CR and structured
training. In CR, this improvement directly benefits targeted areas of
everyday life, whereas the improvements observed following struc-
tured task‐specific training may not generalise to real‐life situations.
Other benefits resulting from CR or structured training are not cap-
tured by available standardised outcome measures. In GREAT, there
are several possible explanations for the lack of change in secondary
outcomes. The finding of no differences in cognitive test scores was
unsurprising as the intervention does not directly seek to improve
cognitive function. As only a small proportion of participants reported
clinical levels of depression or anxiety at baseline, there was little
scope for the intervention to demonstrate improvements in these
domains. The absence of reduction in stress for study partners might
be explained by the fact that the intervention did require effort from
them, both to engage when they may feel they have already tried var-
ious strategies without success and to support the implementation of
strategies through the therapy. However, the qualitative findings were
at odds with the results from secondary outcome measures. The inter-
vention may therefore have provided wider benefits that were not
detected by available standardised measures.
4.3 | Implications
The study shows that people with dementia are able to identify key
goals and are motivated to address them. Readiness to make changes
in these areas predicts outcome and is an important factor forpractitioners to consider at initial assessment. However, only those
provided with structured support are able to make demonstrable
progress in attaining their goals. Engagement in this process is crucial
for progress to be made and is facilitated through the positive rela-
tionship with the practitioner and the encouragement and support
the practitioner provides. The findings demonstrate the potential of
practical interventions to enable people with dementia to function
better in areas that are important to them and that can make a differ-
ence to their lives. While GREAT followed a structured protocol, CR is
not a fixed intervention and can be adapted to different contexts to
meet a variety of needs.5 If CR can be delivered in real‐world practice
in a cost‐effective manner, it could form a component of
postdiagnostic care pathways for those recently diagnosed who
would welcome support to develop strategies for living with demen-
tia, or of community reablement or home care packages for those
with more complex needs.5 | CONCLUSIONS
Individual, goal‐oriented CR enables people with dementia to function
better and more independently in relation to goals targeted in the
therapy. This personalised approach addresses individual concerns in
the home setting and can be applied flexibly to meet different kinds
of need. Enablement is an appropriate objective for services that sup-
port people with dementia, and the application of CR provides a
means of translating this objective into practical support in a way that
is acceptable and relevant to people with dementia and their families.
CR can potentially contribute to improving the choice of interventions
available to people living with dementia who have mild‐to‐moderate
cognitive impairment, helping to address the current gap in provision
of psychosocial interventions.1
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